Wondering why we have a brand new look? We have exciting news - HealthSpotlight has merged with and rebranded as AllMyHealth.
Our shared commitment to supporting rare disease communities with trusted resources and advocacy remains as strong as ever - now under a unified name that reflects our patient-first values.
We collaborate with patient support groups to create advocacy materials and amplify community news and events.
Entrada Therapeutics has made a significant stride in the development of treatments for Duchenne muscular dystrophy. The Food and Drug Administration (FDA) has lifted a clinical hold, allowing the company to proceed with trials for their experimental therapy, ENTR-601-44. This decision by the FDA is a crucial step forward, as it enables the initiation of human trials to evaluate the safety and effectiveness of the therapy. The clearance indicates that the FDA is satisfied with the preclinical data and the proposed trial design, which aims to address the underlying causes of the disease.
The advancement of ENTR-601-44 into clinical trials is a hopeful development for those affected by Duchenne muscular dystrophy. It represents progress in the search for more effective treatments and possibly a future cure. As the trials commence, the focus will be on monitoring patient responses and determining the potential of ENTR-601-44 to improve the quality of life for individuals with this condition. (Neurology Live blog, 2025).
More Info 
Add to Calendar